Regard and Recursion are both AI-driven tools in the healthcare sector but serve distinct purposes; Regard focuses on diagnostic support while Recursion emphasizes drug discovery. Regard has secured $81.4M in Series B funding and employs approximately 95 staff, whereas Recursion has a larger workforce of around 800 employees and features a strong open-source model that encourages innovation.
Best for
Recursion is the better choice when your focus is on biotech and pharmaceutical innovations, making it suited for large teams aiming to expedite drug discovery processes with advanced AI-driven data and computing solutions.
Best for
Regard is the better choice when you need a robust diagnostic and documentation tool integrated seamlessly with healthcare systems, ideal for small to medium healthcare providers seeking improved clinical documentation and decision support.
Key Differences
Verdict
Choose Regard if your organization is a healthcare provider looking for comprehensive diagnostic and documentation assistance to enhance patient care. Opt for Recursion if your focus is on leveraging AI to streamline and innovate within the biotech industry, benefiting from its open-source community and robust multi-agent orchestration capabilities. Both have distinct strengths suited to specific organizational needs.
Recursion
Dive into Recursion's innovative approach to decoding biology. Join our mission & explore what AI drug discovery companies can do. Contact us
User reviews and social mentions about "Recursion" mainly highlight its innovative approach to AI with unique features such as recursive observation and multi-agent orchestration. The main strength noted is the tool's ability to manage complex AI tasks efficiently through these recursive methodologies. However, some users express skepticism about its ability to compete with well-established solutions, particularly concerning AI consciousness and vulnerabilities. Pricing sentiment is not explicitly mentioned, but the tool's open-source nature suggests a positive reception. Overall, Recursion has a reputation for being a cutting-edge, open-source platform with a niche following among tech enthusiasts and developers.
Regard
Regard reviews all data in the medical record to recommend diagnoses and generate a complete note at the point of care - improving care, quality, and
The reviews and social mentions do not provide any specific feedback or insights about "Regard", making it challenging to discern user opinions on the software. Given the lack of detailed user input, it is difficult to outline the main strengths, key complaints, pricing sentiment, or overall reputation of the tool. More targeted user feedback would be needed for a comprehensive analysis.
Recursion
-67% vs last weekRegard
Stable week-over-weekRecursion
Regard
Recursion
Regard
Recursion
Regard
Pricing found: $7
Recursion (1)
Regard (2)
Only in Recursion (10)
Only in Regard (2)
Only in Recursion (8)
Only in Regard (8)
Recursion
Regard
Recursion
Regard
Recursion
AI’s Current Proof Points in Drug Discovery – and the Next Frontier
Mar 26, 2026
Highlights from Recursion's Evening of Hope Event for Rare Disease Day 2026
Mar 24, 2026
An Evening of Hope: 2026 Rare Disease Day Event at Recursion
Mar 23, 2026
Recursion's Era of Value Realization: CFO Ben Taylor at Leerink Global Healthcare Conference
Mar 18, 2026
Regard
No YouTube channel
Recursion
Regard
Recursion
Regard
Recursion
The Mundane Risk
*The biggest near-term AI safety risks aren't dramatic — they're mundane. And that's precisely why they're* ***neglected****. This essay argues three things: (1) mundane AI failures are already causing measurable damage at scale, (2) current alignment approaches may depend more heavily on sandboxed
Regard
Is Flock just a poor US-centric copy of, globally active Genetec?
I've read all of Genetec's [customer stories](https://www.genetec.com/customer-stories/search) (the PDFs), and although I recognize these, as being Genetec marketing material (at least in part), they do contain insightful information, regarding implementation of surveillance systems; that is, from t
Shared (1)
Only in Recursion (1)
Regard excels in this area with integrated support for Electronic Health Records and other healthcare-specific platforms.
Regard uses a tiered pricing model starting at $7, while Recursion's open-source foundation may offer more cost-effective entry without explicit pricing details.
Recursion likely has superior community support thanks to its open-source ecosystem fostering extensive collaboration and innovation.
While they serve different functions, coordination between diagnostic and drug discovery efforts theoretically allows for complementary use cases, especially in integrated healthcare solutions.
Getting started might be easier with Recursion for those familiar with AI and open-source tools, whereas Regard targets healthcare providers and might require adaptation to existing systems.
